The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model

RATIONAL: cMet is abnormally regulated in gastrointestinal cancer, and is associated with increased invasiveness of the disease and poor overall survival. There are indications that targeted therapy against cMet, alone or in combination with additional cancer therapies, can help improve treatment ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiegelberg, Diana, Mortensen, Anja Charlotte Lundgren, Palupi, Kartika Dyah, Micke, Patrick, Wong, Julin, Vojtesek, Borivoj, Lane, David Philip, Nestor, Marika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516085/
https://www.ncbi.nlm.nih.gov/pubmed/33014851
http://dx.doi.org/10.3389/fonc.2020.01717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516085/
https://www.ncbi.nlm.nih.gov/pubmed/33014851
http://dx.doi.org/10.3389/fonc.2020.01717

Ejemplares similares